{
    "Clinical Trial ID": "NCT00470301",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I",
        "  See Detailed Description",
        "  tipifarnib: Given orally",
        "  paclitaxel: Given IV",
        "  doxorubicin hydrochloride: Given IV",
        "  cyclophosphamide: Given IV",
        "  pegfilgrastim: Given SC",
        "  conventional surgery: surgical procedures performed on patients",
        "  axillary lymph node dissection: correlative study"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed adenocarcinoma of the breast; clinical stage IIB, IIIA, IIIB, or IIIC disease",
        "  At least 1 week since prior tamoxifen or other selective estrogen receptor modulator for prevention or for other indications (e.g., osteoporosis or prior ductal carcinoma in situ)",
        "  HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization (FISH)",
        "  Hormone receptor status:",
        "  Estrogen and/or progesterone receptor-positive* [Note: *Patients enrolled on the phase I portion of the trial may have estrogen and progesterone receptor-negative disease]",
        "  Normal organ function including:",
        "  WBC >= 3,000/mm^3",
        "  Absolute neutrophil count >= 1,500/mm^3",
        "  Platelet count >= 100,000/mm^3",
        "  Bilirubin normal",
        "  AST and ALT =< 2.5 times upper limit of normal",
        "  LVEF normal by echocardiogram or nuclear scan",
        "  Creatinine normal OR Creatinine clearance >= 60 mL/min",
        "  FEV1 >= 1 L* and DLCO >= 50%* [Note: *Only if baseline CT scan of chest shows parenchymal lung disease OR there is a history of chronic obstructive or other pulmonary disease]",
        "  No prior chemotherapy, radiotherapy, or definitive therapeutic surgery (e.g., mastectomy, lumpectomy, or axillary dissection) for this cancer but prior sentinel lymph node biopsy for this malignancy allowed",
        "  No prior adjuvant chemotherapy for a previous breast malignancy",
        "  No concurrent combination antiretroviral therapy for HIV-positive patients",
        "  No other concurrent investigational agents",
        "  No other concurrent anticancer agents or therapies",
        "  ECOG performance status 0-1",
        "  Fertile patients must use effective contraception",
        "Exclusion criteria:",
        "  No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix",
        "  No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs (e.g., imidazoles or quinolones)",
        "  No other uncontrolled illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would preclude study compliance",
        "  Not pregnant or nursing"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Pathologic Complete Response Rate (pCR)",
        "  An increase in the breast pCR from 15% (anticipated for chemotherapy alone) to 35% would be considered promising.",
        "  Time frame: Up to 5 years",
        "Results 1: ",
        "  Arm/Group Title: Arm I",
        "  Arm/Group Description: See Detailed Description",
        "  tipifarnib: Given orally",
        "  paclitaxel: Given IV",
        "  doxorubicin hydrochloride: Given IV",
        "  cyclophosphamide: Given IV",
        "  pegfilgrastim: Given SC",
        "  conventional surgery: surgical procedures performed on patients",
        "  axillary lymph node dissection: correlative study",
        "  Overall Number of Participants Analyzed: 55",
        "  Measure Type: Number",
        "  Unit of Measure: participants  33        (7 to 36)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 13/60 (21.67%)",
        "  Neutropenia 13/60 (21.67%)"
    ]
}